BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.

Promore Pharma (STO:PROMO) (FRA:8T0) The Board of Directors of Emplicure AB has decided to change the date of the company’s Annual General Meeting to June 27, 2023.

Arbutus Biopharma Corporation today announced that it has scheduled its first quarter 2023 financial results and corporate update for Thursday, May 4, 2023.

Sensei Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, paving the way for the Company to conduct a Phase 1/2 clinical trial in patients with solid tumors.

Blue Water Vaccines Inc. today announced the signing of an Asset Purchase Agreement (the “Agreement”) with Veru Inc. (“Veru”) for the purchase of ENTADFI®.

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023.

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

BetterLife Pharma Inc. is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the upcoming Bloom Burton Healthcare Investor Conference on Wednesday April 26, 2023 in Toronto, Ontario, Canada.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023), to be held April 23-27, 2023, in New Orleans, Louisiana.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023.